HOTH THERAPEUTICS, INC.

Insiders Hoth Therapeutics, Inc.

Equities

HOTH

US44148G2049

Delayed Nasdaq Other stock markets 15:15:45 10/05/2024 BST			5-day change	1st Jan Change
1.19 ^USD	-0.83%		-1.65%	-17.36%

03-28	Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-19	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hoth Therapeutics, Inc. Announces Board Changes	13/12/22	CI
Hoth Therapeutics, Inc. Announces Scientific Advisory Board Appointments	31/01/22	CI
Vadim Mats to Resign from the Board of Directors of Hoth Therapeutics, Inc	21/01/22	CI
Hoth Therapeutics Announces the Appointment of Mario E. Lacouture to its Scientific Advisory Board	27/01/21	CI
Hoth Therapeutics, Inc. Appoints Stefanie Johns as Chief Scientific Officer, Effective as of September 8, 2020	31/08/20	CI
Hoth Therapeutics, Inc. Announces the Resignation of Kenneth Rice from Board of Directors, Effective September 30, 2020	18/08/20	CI
Hoth Therapeutics, Inc. Appoints Michael Peters to Scientific Advisory Board	22/05/20	CI
Hoth Therapeutics, Inc. Announces Board Changes	17/04/20	CI
Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board	17/12/19	CI
Hoth Therapeutics, Inc. Appoints Jonathan Zippin as Senior Scientific Advisor	11/03/19	CI
Hoth Therapeutics, Inc. Appoints David Briones as Chief Financial Officer	07/03/19	CI
Hoth Therapeutics Inc. Adds Richard D. Granstein to the Technology Advisory Board	16/10/17	CI
Hoth Therapeutics Inc. Announces the Addition of Dr. Andrew Herr to its Technology Advisory Board	05/09/17	CI
Hoth Therapeutics Inc. Appoints Anthony Hayes as Board of Director	27/07/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer